0RP.F TIZIANA LIFE SCIENCES LTD
- Market cap
- EUR 69.4M
- P/E
- -
- P/B
- 2,465.72x
- ROE
- -35,444.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 0RP.F undervalued?
Graham numberThe Graham number of TIZIANA LIFE SCIENCES LTD cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
TIZIANA LIFE SCIENCES LTD fundamental analysis
No fundamental analysis for TIZIANA LIFE SCIENCES LTD yet.
TIZIANA LIFE SCIENCES LTD stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About TIZIANA LIFE SCIENCES LTD
Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a …
Full company profileTIZIANA LIFE SCIENCES LTD financial statements
TIZIANA LIFE SCIENCES LTD annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | - | - | - | - |
| Operating Income | -27.4M | -14.6M | -18.0M | -15.8M | -21.1M |
| EBITDA | - | -15.3M | -17.1M | -16.6M | -18.2M |
| Net Income | -23.4M | -15.4M | -17.7M | -11.9M | -18.4M |
| EPS | -0.23 | -0.15 | -0.17 | -0.11 | -0.15 |
| Balance Sheet | |||||
| Total Assets | 48.8M | 26.5M | 12.2M | 11.3M | 11.5M |
| Total Liabilities | 7.55M | 6.91M | 6.65M | 7.35M | 11.4M |
| Shareholders' Equity | 41.3M | 19.6M | 5.54M | 3.94M | 52.0K |
| Cash & Short-term Investments | 42.2M | 18.1M | 1.18M | 3.72M | 4.01M |
| Cash Flow | |||||
| Operating Cash Flow | -21.8M | -19.6M | -15.7M | -1.53M | -12.8M |
| Capital Expenditure | 22.0K | 0.00 | 0.00 | 19.0K | 21.0K |
| Free Cash Flow | -21.8M | -19.6M | -15.7M | -1.55M | -12.9M |
| Ratios | |||||
| ROE | -56.7% | -78.7% | -319.6% | -301.4% | -35,444.2% |
| ROA | -48.0% | -58.2% | -145.2% | -105.1% | -160.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
TIZIANA LIFE SCIENCES LTD dividends
TIZIANA LIFE SCIENCES LTD has not paid dividends in the last 6 fiscal years.
Last stock split: 2.5:1 on Jul 31, 2020.
Who owns TIZIANA LIFE SCIENCES LTD
- Insiders 47.36%
- Institutions 1.93%
- Public & others 50.71%
- Shares outstanding 127M
- Free float 64.1M
TIZIANA LIFE SCIENCES LTD company profile
- Company name
- TIZIANA LIFE SCIENCES LTD
- Ticker
- 0RP.F
- ISIN
- BMG889121031
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 10
- Fiscal year end
- December
- Address
- 14/15 Conduit Street, London, United Kingdom, W1S 2XJ
- Phone
- 44 20 7495 2379
- Website
- tizianalifesciences.com
About TIZIANA LIFE SCIENCES LTD
Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases. The company is headquartered in London, the United Kingdom.
TIZIANA LIFE SCIENCES LTD management
6- Mr. Gabriele Marco Antonio Cerrone M.B.A.Founder & Executive Chairman · born 1972
- Ms. Keeren ShahCOO & CFO · born 1976
- Dr. Ivor R. Elrifi Ph.D.CEO & Executive Director
- Mr. William Edward Tente M.S.Chief Regulatory Officer · born 1958
- Dr. Richard K. Kim M.D.Chief Medical Officer · born 1971
- Dr. Napoleone Ferrara M.D.Member of Scientific Advisory Board · born 1957